BiotechTube

200 mg of pembrolizumab + V938

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm Metastasis

Conditions

Neoplasm Metastasis

Trial Timeline

Nov 4, 2019 → Aug 24, 2022

NCT ID
NCT04135352

About 200 mg of pembrolizumab + V938

200 mg of pembrolizumab + V938 is a phase 1 stage product being developed by Merck for Neoplasm Metastasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04135352. Target conditions include Neoplasm Metastasis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04135352Phase 1Terminated

Competing Products

20 competing products in Neoplasm Metastasis

See all competitors
ProductCompanyStageHype Score
AB0024Gilead SciencesPhase 1
32
TTI-237PfizerPhase 1
32
852APfizerPhase 1
32
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
32
LY2780301Eli LillyPhase 1
33
PemetrexedEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 1/2
41
IMC-3C5Eli LillyPhase 1
33
LY3295668Eli LillyPhase 1/2
41
Abemaciclib + ClarithromycinEli LillyPhase 1
33
Abemaciclib + FulvestrantEli LillyPhase 2
52
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
41
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
33
LY2784544Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
enzastaurinEli LillyPhase 2
52
enzastaurin + gemcitabineEli LillyPhase 2
52
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85